martes, 23 de agosto de 2016

National Institute on Aging | The Leader in Aging Research

National Institute on Aging | The Leader in Aging Research

e-Update from the Alzheimer's Disease Education and Referral Center, a service of the National Institute on Aging at N I H

The two biggest risk factors for late-onset Alzheimer’s
disease—age and carrying a risk gene—can’t be changed.
But what if people could do something to counteract those
risks and possibly tip the balance in their favor? A
groundbreaking clinical trial aims to find out if two experimental
drugs can prevent or delay dementia in people at high genetic
risk for developing the disorder.

The Alzheimer’s Prevention Initiative’s (API) Generation Study
is seekingcognitively normal older adults with two copies of the
APOE ɛ4 gene. People with two copies of this risk-factor gene
are more likely than not to develop late-onset Alzheimer’s, the
most common form of the brain disorder, which so far has no cure.

Read the full article to learn more about the Generation Study
and how to volunteer.

No hay comentarios:

Publicar un comentario